CYP24A1 and glaucoma: Notably, the first two aforementioned bioactive compounds, oleuropein and verbascoside, exhibited a significant inhibitory effect at low μM concentrations in vitro against human carbonic anhydrase I and II (hCA I and II) isoenzymes [200], which are therapeutic targets against glaucoma and their inhibition is considered a therapeutic strategy against glaucoma [201].